OpenAI announces that from today advertisers can purchase ChatGPT ads directly through the manager in Europe, India the Middle East and North Africa
Newsquawk Staff ·
OpenAI announces that from today advertisers can purchase ChatGPT ads directly through the manager in Europe, India the Middle East and North Africa.
What it means
Rollouts of self-serve ad buying across new regions are how platform monetisation typically scales: the sequence has historically been pilot in one market, then a self-serve manager, then geographic extension, with revenue contribution lagging the launch by several reporting periods. The read-through for listed comparables runs through the digital advertising peer set, where a credible new entrant with a large engaged user base has in past episodes compressed sentiment around incumbent search and social ad franchises, since the spend pool is largely reallocative rather than additive. OpenAI remains private, so the transmission to public markets is indirect, principally through the Microsoft relationship and through second-order effects on the ad-dependent mega-caps. What is worth watching is advertiser adoption commentary, any disclosure of pricing or format, and whether the company reports monetisation metrics in future funding or valuation discussions. As a product announcement rather than a financial disclosure, the immediate signal is directional.
- OpenAI expects future AI models to be capable of identifying and exploiting vulnerabilities that are currently unknown, according to a blog post
- Texas Attorney General Ken Paxton sues OpenAI and CEO Sam Altman for lying to users and harming Texans
- OpenAI reveals plans for an in-house exabyte-scale storage system
- CrowdStrike (CRWD) CEO says in the coming months we will see a lot of breaches from the PHP vulnerability
- Oracle (ORCL) to invest USD 1bln in partner ecosystem over 4 years
Related headlines
- Newsquawk Weekly Economic Release 26th - 30th October 2026 11 hours ago
- Daily US Earnings Estimates: 26th October 2026: VZ, WELL7 hours ago
- Kimi K3.1 Pro AI model builds GTA VI-style (TTWO) playable game demo in just 10 hours for USD 52, developer claims on X; showcases AI’s ability to generate video game experiences - UNCONFIRMED6 hours ago
- The Trump administration plans to introduce voluntary “US Caught Seafood” labels to help consumers identify seafood origins, according to CBS9 hours ago
- Republican Senator Blackburn has raised concerns about Meta’s (META) plans to update its commercial terms, warning that the changes could “exploit American creators and businesses,” according to a letter9 hours ago
- CNBC speculates that Verizon (VZ) would most likely be involved in the context of a partnership with SpaceX (SPCX)10 hours ago
- Ukraine President Zelensky says the Tesla (TSLA)/SpaceX (SPCX) Starlink and Starshield service remains slowed10 hours ago
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce11 hours ago
- Meta (META) says it will extend the implementation date of updated commercial terms to November 20th (prev. October 30th); extension will allow it to explain the changes to partners and stakeholders12 hours ago
- US FDA approves subcutaneous induction regimen for AbbVie’s (ABBV) Skyrizi for adults with moderately to severely active Crohn’s disease5 hours ago
- Bristol Myers Squibb (BMY) spokesperson says the company has identified the cause of an earlier Car-T safety signal; will look to resume the paused trials in 20279 hours ago
- Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer12 hours ago
- Daily US Equity Opening News: SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at $1.25T valuation12 hours ago
- US BROKER MOVES: HESM upgraded at Raymond James; NCLH downgraded at JPM12 hours ago
- Bristol-Myers Squibb (BMY) says Iza-Bren reduced the risk of progression or death by 59% in Phase 3 breast cancer study; median PFS 8.2 months vs 4.0 months for chemotherapy; cORR 40.5% vs 20.2%; mDOR 6.9 vs 4.2 months13 hours ago